Armistice Capital’s LinkedIn Trajectory: Navigating Biotech Investments and Market Shifts
Armistice Capital has emerged as a notable player in the ever-evolving landscape of hedge fund investments, particularly in biotech and healthcare. As the dust settles from the pandemic-induced biotech boom, the sector appears primed for a potential resurgence in 2024, with Armistice Capital at the forefront of this anticipated upturn. Continue Reading